Focus


Assembling the pieces

'Big science' initiatives and investigator-driven 'small science' research in chemical biology will both contribute to a more integrated view of biological systems.

Top

Editorial

Assembling the pieces

Assembling the pieces p321

doi:10.1038/nchembio.593

Balancing big science projects with smaller-scale mechanistic studies provides a collaborative approach for integrating scientific knowledge and addressing major scientific challenges.


Top

Commentaries

Assembling the pieces

Social engineering for virtual 'big science' in systems biology pp323 - 326

Hiroaki Kitano, Samik Ghosh & Yukiko Matsuoka

doi:10.1038/nchembio.574

A new type of big science is emerging that involves knowledge integration and collaboration among small sciences. Because open collaboration involves participants with diverse motivations and interests, social dynamics have a critical role in making the project successful. Thus, proper 'social engineering' will have greater role in scientific project planning and management in the future.


Assembling the pieces

An active role for machine learning in drug development pp327 - 330

Robert F Murphy

doi:10.1038/nchembio.576

Because of the complexity of biological systems, cutting-edge machine-learning methods will be critical for future drug development. In particular, machine-vision methods to extract detailed information from imaging assays and active-learning methods to guide experimentation will be required to overcome the dimensionality problem in drug development.


Assembling the pieces

A postreductionist framework for protein biochemistry pp331 - 334

Tom Laue & Borries Demeler

doi:10.1038/nchembio.575

As biochemistry ventures out from its reductionist roots, concentration effects and high surface-to-volume ratios will challenge our current understanding of biological systems, with colloidal and surface chemistry leading to new insights and approaches. How must our thinking change, what new tools will we need and how will these new tools be developed?


Assembling the pieces

Getting pharmaceutical R&D back on target pp335 - 339

Mark E Bunnage

doi:10.1038/nchembio.581

The pharmaceutical industry is in a period of crisis due to the low number of new drug approvals relative to the high levels of R&D investment. It is argued here that improving the quality of target selection is the single most important factor to transform industry productivity and bring innovative new medicines to patients.


Extra navigation

natureevents